Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?

580 Background: BRCA1 being involved in DNA repair and apoptosis, its mutations may influence response to chemotherapy. In vitro studies demonstrated that loss of BRCA1 function increased sensitivity to platinum compounds and induced resistance to anthracyclines. BRCA1-related breast cancers tend to be ductal carcinomas with high tumor grade, absence of hormonal receptors and no HER2 overexpression, so called triple-negative. We retrospectively analyzed anthracycline-based neoadjuvant chemotherapy efficacy in triple- negative tumors according to BRCA1 status. Methods: 393 breast cancer pts were treated with FEC100 neoadjuvant chemotherapy (FU 500 mg/m2, epirubicine 100 mg/m2, cyclophosphamide 500 mg/m2) between 1/2000 and 12/2006. Out of them, 14% had a triple-negative phenotype (55 pts). Patients with young age at diagnosis or family history of breast cancer were offered genetic testing for BRCA1 and BRCA2 mutations. Twelve of these patients had a BRCA1 deleterious mutation with a triple-negative tumor. Characteristics of these 12 pts at diagnosis were: median age = 38, tumor stage = 7 T2N0, 2 T2N1, 2 T3N0, 1 T3N1. Results: Pathological complete response was defined as absence of invasive tumor in breast and axillary nodes. After 6 cycles of FEC100, 42% of patients with triple-negative tumors (23/55) had a pathological complete response, compared to 17% (2/12) with a BRCA1 mutation. Only one of the 12 BRCA1 patients had an axillary node involvement. Conclusions: In our series, BRCA1 deleterious mutations decreased anthracycline-based chemotherapy efficacy in triple- negative breast cancers. Platinum compounds should be evaluated in these BRCA1-related tumors. No significant financial relationships to disclose.

Download Full-text

PROGNOSIS OF NEOADJUVANT CHEMOTHERAPY EFFICACY WITH IMMUNOBIOLOGIC TUMOR MARKERS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER

Likarska sprava ◽

10.31640/jvd.5-6.2019(5) ◽

2019 ◽

pp. 46-54

Author(s):

S. A. Lyalkin ◽

N. O. Verevkina ◽

L. A. Syvak

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Fold Increase ◽

Predictive Role ◽

High Level ◽

Chemotherapy Efficacy ◽

Cd4 Lymphocytes

Treatment of patients with triple negative breast cancer (TNBC) remains one of the most difficult problems in clinical oncology. Despite the negative prognosis for TNBC, there exists the group of patients with better response to the therapy and better prognosis, which proves the heterogenity of TNBC. The aim of the study was to evaluate the predictive role of tumor infiltrative lymphocytes (TIL) and their subpopulations (CD4+, CD8+ and FOXP3) in patients with TNBC. The predictive role of clinical, morphologic and immunohystochemical tumor features on neoadjuvant chemotherapy (NACT) efficacy was assessed in 52 TNBC patients. The risk of incomplete pathomorphologic response after NACT is related with 2 biomarkers: level of TIL and stromal CD4+ lymphocytes. The increase of TIL level decreases of the risk of incomplete pathomorphologic response (P = 0.01), ОR = 0.07 (95 % CІ 0.01–0.55) while standartization on CD4+ level. The high level of TIL at the time of diagnosis significantly decreases the risk of incomplete pathomorphologic response (OR = 0,2; P = 0,02). The group of patients with the ratio of stromal lymphocytes CD4low/CD8low had the eight-fold increase of the risk of incomplete pathomorphologic response comparing with the group with the ratio CD4high/CD8high (ОR = 8,0; Р = 0,03); the patient with the ratio stromal lymphocytes CD8low/ FOXP3low had the almost two-fold increase of the risk of incomplete pathomorphologic response comparing with the group with the ratio CD8high/FOXP3high (ОR = 2,1; Р = 0,03).

Download Full-text

Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy

Medicine ◽

10.1097/md.0000000000011647 ◽

2018 ◽

Vol 97 (30) ◽

pp. e11647 ◽

Cited By ~ 12

Author(s):

Young Jae Ryu ◽

Shin Jae Kang ◽

Jin Seong Cho ◽

Jung Han Yoon ◽

Min Ho Park

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Lymphovascular Invasion ◽

Pathologic Complete Response ◽

Complete Response ◽

Better Than

Download Full-text

Correlation of sTILs Infiltration and UBR5 Expression on the Efficacy of Neoadjuvant Chemotherapy Efficacy and Prognosis in Early Triple Negative Breast Cancer

10.21203/rs.3.rs-142859/v1 ◽

2021 ◽

Author(s):

Jian Pang ◽

Li Zhou ◽

Liqiu Liao ◽

Shouman Wang

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Chemotherapy Resistance ◽

Tumor Infiltrating Lymphocytes ◽

Mouse Breast Cancer ◽

Immune Related Genes ◽

The Relationship ◽

Chemotherapy Efficacy

Abstract Neoadjuvant chemotherapy (NAC) is widely used in patients with TNBC, but there are significant differences in the efficacy of chemotherapy in different patients. Stromal tumor infiltrating lymphocytes (sTILs) have been widely studied as biomarkers reflecting the therapeutic effect of NAC. As a tumor-associated gene, UBR5 has been found to be associated with chemotherapy sensitivity and prognosis of many cancers. This is the first time that we have combined UBR5 and sTILs to evaluate the chemotherapy efficacy of patients with TNBC treated with NAC and to study the correlation between sTILs and UBR5. MethodsSPSS was used to analyze the correlation between UBR5 and sTILs and clinicopathological data. Then doxorubicin and mitoxantrone treated mouse breast cancer cells to explore the relationship between UBR5 expression and chemotherapeutic drug sensitivity. Finally, R language analyzes the relationship between UBR5 and immune-related genes and immune score.ResultsIn patients with TNBC treated with NAC, the expression level of UBR5 and the degree of infiltration of sTILs are independent factors that affect whether the patient can achieve PCR and the expression between the two is negatively correlated. UBR5 expression can cause mouse breast cancer cells to develop resistance to doxorubicin and mitoxantrone. At the same time, UBR5 is also highly correlated with a variety of immune-related genes and immune scores.ConclusionUBR5 and sTILs can jointly predict the efficacy of NAC in patients with TNBC. At the same time, the expression of UBR5 is also an important reason for chemotherapy resistance in patients with TNBC.

Download Full-text

Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy

International Journal of Breast Cancer ◽

10.1155/2015/147476 ◽

2015 ◽

Vol 2015 ◽

pp. 1-7 ◽

Cited By ~ 1

Author(s):

Shravan Kandula ◽

Jeffrey M. Switchenko ◽

Saul Harari ◽

Carolina Fasola ◽

Donna Mister ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Endocrine Therapy ◽

Locoregional Recurrence ◽

Lymphovascular Invasion ◽

Triple Negative ◽

Adjuvant Endocrine Therapy ◽

Breast Cancer Patients ◽

Nodal Disease

Among breast cancer patients treated with neoadjuvant chemotherapy (NAC) and mastectomy, locoregional recurrence (LRR) rates are unclear in women with ER+ tumors treated with adjuvant endocrine therapy without postmastectomy radiation (PMRT). To determine if PMRT is needed in these patients, we compared LRR rates of patients with ER+ tumors (treated with adjuvant endocrine therapy) with women who have non-ER+ tumors. 85 consecutive breast cancer patients (87 breast tumors) treated with NAC and mastectomy without PMRT were reviewed. Patients were divided by residual nodal disease (ypN) status (ypN+ versus ypN0) and then stratified by receptor subtype. Among ypN+ patients (n=35), five-year LRR risk in patients with ER+, Her2+, and triple negative tumors was 5%, 33%, and 37%, respectively (p=0.02). Among ypN+/ER+ patients, lymphovascular invasion and grade three disease increased the five-year LRR risk to 13% and 11%, respectively. Among ypN0 patients (n=52), five-year LRR risk in patients with ER+, Her2+, and triple negative tumors was 7%, 22%, and 6%, respectively (p=0.71). In women with ER+ tumors and residual nodal disease, endocrine therapy may be sufficient adjuvant treatment, except in patients with lymphovascular invasion or grade three tumors where PMRT may still be indicated.

Download Full-text

Lymphovascular invasion in breast cancer after neoadjuvant chemotherapy. Review of 284 cases

10.26226/morressier.596dfd56d462b8029238712a ◽

2017 ◽

Author(s):

Nikaoly de Los Ángeles Ciriaco Cortés

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Lymphovascular Invasion

Download Full-text

Effects of MDR1 Gene Polymorphism on Efficacy and Hematotoxicity of Epirubicin-Based Regimen in Patients with Breast Cancer in Southwest China

Clinical Oncology and Research ◽

10.31487/j.cor.2021.04.04 ◽

2021 ◽

pp. 1-8

Author(s):

Yilan Huang ◽

Qiming Wei ◽

Xiaoyan Zhong ◽

Wanlong Zhu ◽

Qingze Fan ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Southwest China ◽

Chemotherapy Regimen ◽

Multi Drug Resistance ◽

Hematological Toxicity ◽

C3435t Polymorphism ◽

Flight Mass Spectrometry ◽

Mdr1 Polymorphism ◽

Chemotherapy Efficacy

Objective: To investigate the predictive value of multi-drug resistance gene (MDR1) polymorphism in the efficacy and hematological toxicity of chemotherapy regimen based on Epirubicin in patients with breast cancer in Southwest China. Methods: Patients who received Epirubicin-based chemotherapy were included, and polymorphism of C1236T, G2677T/A and C3435T were detected by time-of-flight mass spectrometry (TOF-MS). The correlation between different genotypes and chemotherapy efficacy and blood toxicity were evaluated. Results: A total of 102 patients were included, 44 of them were treated with neoadjuvant chemotherapy. There was no significant correlation between all genotypes and alleles of the three SNPs and the efficacy of neoadjuvant chemotherapy regimen containing Epirubicin in patients with breast cancer. There was a significant correlation between C3435T polymorphism and grade Ⅲ-Ⅳ leukopenia in patients with breast cancer, the incidence of grade Ⅲ-Ⅳ leukopenia in patients with C allele was significantly lower than that in patients with T allele. Conclusion: T allele of C3435T polymorphism may be a risk factor for grade Ⅲ-Ⅳ leukopenia in patients with breast cancer after chemotherapy.

Download Full-text